Unani treatment for non alcoholic fatty liver

Efficacy of Habb-e-Ghafis in Non Alcoholic Fatty Liver Disease--Randomized Single Blind Placebo Controlled Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/06/053931

Enrollment

Registered

2023-06-15

Start date

Unknown

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

Intervention1: Habb e Ghafis: 1. Gul-e-Ghafis Gentiana Olivier Griseb. 1 part 2. Sibr Saqootri Aloe barbadensis Mill. 1 part 3. Post Halela Zard Terminalia chebula Retz. 1 part

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed cases of fatty liver (Grade-I and Grade-II) by USG. Patients of any gender Age group of 20-60 years Pain / Heaviness in right hypochondriac region Non-alcoholic patients Controlled DM

Exclusion criteria

Exclusion criteria: Fatty liver Grade-III Pregnant and Lactating mother K/h/o Positive Hepatitis Patients suffering from Hepatic Cancer.

Design outcomes

Primary

Measure	Time frame
Decrease in size of liver in USG of Abdomen Timepoint: 60 days	—

Secondary

Measure	Time frame
Lipid profileTimepoint: 60 days	—

Countries

India

Contacts

Public ContactDr Mohd Aleemuddin Quamri

National Institute of Unani Medicine

drmaquamri@gmail.com9341072974

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026